U.S. Logistics Stock News

NYSE:LAD
NYSE:LADSpecialty Retail

Does Lithia Motors' (LAD) Rising EPS Amid Lower Profits Redefine Its Capital Return Narrative?

Lithia Motors, Inc. reported past second-quarter 2026 results showing revenue of US$9,791.3 million and net income of US$260 million, alongside updates on its dividend and share repurchases. An interesting takeaway is that while six-month net income fell to US$360.4 million, diluted EPS for the second quarter still increased, supported by significant share buybacks. Next, we’ll examine how Lithia’s higher quarterly EPS, combined with continued share repurchases, may shape its existing...
NYSE:LDOS
NYSE:LDOSProfessional Services

Is Leidos Holdings (LDOS) Below Fair Value Following Its CoreWeave Deal And Air Force Win?

Leidos Holdings (LDOS) is back in focus after a busy week that included a new sovereign AI cloud alliance with CoreWeave, the Parcata autonomous cybersecurity platform launch, and a large U.S. Air Force ISR task order. See our latest analysis for Leidos Holdings. Despite the fresh AI alliance, Parcata launch, and new ISR task order, Leidos Holdings’ share price has been under pressure, with a 90 day share price return down 22.5% and a year to date share price return down 37%, even though the...
NasdaqGS:BAND
NasdaqGS:BANDTelecom

Bandwidth (BAND) Turns Profitable On Raised Outlook While Fair Value Debate Builds

Bandwidth (BAND) is back in focus after reporting second quarter 2026 results that shifted from loss to profit and prompted the company to raise its full year revenue guidance. See our latest analysis for Bandwidth. Bandwidth’s latest earnings and raised revenue guidance come after a sharp pullback, with the 7 day share price return down 34.55% and the 30 day share price return down 38.64%, even though the year to date share price return is 175.25% and the 1 year total shareholder return is...
NasdaqGS:CINF
NasdaqGS:CINFInsurance

How Robust Q2 2026 Earnings and Buybacks Will Impact Cincinnati Financial (CINF) Investors

Cincinnati Financial Corporation reported second-quarter 2026 results, with revenue rising to US$4,274 million and net income to US$1,255 million, while also completing US$214.91 million of share repurchases between April and June. Over the first half of 2026, the company generated US$7,137 million in revenue and US$1,529 million in net income, highlighting how earnings strength and ongoing buybacks have jointly reshaped its capital and earnings profile. With this strong earnings performance...
NasdaqGS:AMRX
NasdaqGS:AMRXPharmaceuticals

Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance

Amneal Pharmaceuticals stock has delivered a very strong 345.7% return over the past 3 years, yet its valuation checks lean more on the expensive side rather than flagging it as a clear bargain. Over the last 3 years Amneal Pharmaceuticals has returned 345.7%, which puts extra focus on whether the current share price already reflects much of the good news. Recent earnings strength and higher expectations for future revenue and profit can support the current valuation, but any disappointment...
NYSE:DAR
NYSE:DARFood

Darling Ingredients (DAR) Could Be 20% Undervalued After Strong Q2 Earnings

Darling Ingredients (DAR) just delivered a sharp second quarter earnings improvement, supported by higher margin performance, strong demand in core segments, and continued strength from Diamond Green Diesel. The results also coincided with completed buybacks and lower debt. See our latest analysis for Darling Ingredients. Despite a slight 1-day share price decline of 0.59% and a 7-day share price return that is down 2.98%, Darling Ingredients has built strong momentum with a 61.11% year to...
NYSE:EFOR
NYSE:EFORIT

Everforth (EFOR): Do Buybacks Amid Softer Earnings Reveal Management’s True View on Risk and Reward?

In late July 2026, Everforth, Inc. reported second-quarter 2026 results showing sales of US$1,007.0 million and net income of US$14.2 million, issued third-quarter guidance for revenues of US$994.0 million to US$1,024.0 million and net income of US$14.5 million to US$23.0 million, and confirmed diluted EPS guidance of US$0.36 to US$0.56. Alongside softer earnings, Everforth completed a US$77.5 million buyback of 1,796,224 shares, highlighting management’s continued focus on returning capital...
NYSE:DY
NYSE:DYConstruction

Dycom Industries (DY) Stock Could Be Slightly Below Fair Value

Dycom Industries has rewarded long term shareholders with a very large 5 year return, yet the latest valuation work sends a mixed signal, with the Discounted Cash Flow (DCF) estimate pointing to the stock trading below intrinsic value while the broader checks lean away from a clear bargain. Over the past 5 years, Dycom Industries has delivered a total return of about 4.5x, which puts extra attention on whether the current price already reflects much of that success. Expectations for...
NYSE:GHC
NYSE:GHCConsumer Services

Graham Holdings (GHC) Could Be 60% Undervalued On Strong Q2 Earnings

Q2 earnings highlight sharp move in profitability Graham Holdings (GHC) has drawn fresh attention after reporting second quarter 2026 earnings, with revenue of US$1.3b and net income of US$281.1m, compared with US$1.2b and US$36.75m a year earlier. See our latest analysis for Graham Holdings. Graham Holdings' recent results landed against a share price of US$1,203.54, with the 7 day share price return of 4.21% and 90 day share price return of 6.09% sitting alongside a 1 year total shareholder...
NasdaqGS:BUSE
NasdaqGS:BUSEBanks

What First Busey (BUSE)'s Profit Jump, Lower Charge-Offs and Buybacks Mean For Shareholders

First Busey Corporation recently reported second-quarter 2026 results showing slightly lower net interest income of US$152.4 million year on year but a sharp rise in net income to US$63.18 million, alongside reduced net charge-offs of US$6.382 million versus the prior period. Alongside stronger earnings, First Busey continued returning capital by completing a long-running repurchase program totaling 11,767,892 shares for US$288.85 million while also announcing the forthcoming retirement of...
NYSE:MUX
NYSE:MUXMetals and Mining

Is McEwen (MUX) Undervalued After Its Paragon Labs Partnership?

McEwen (MUX) stock is in focus after the company agreed to a new partnership with Paragon Advanced Labs to build PhotonAssay equipped laboratory facilities around its Gold Bar Mine Complex in Nevada, with possible extensions to Ontario and Mexico. See our latest analysis for McEwen. Alongside this new Paragon Advanced Labs partnership, McEwen’s share price has slipped 18.83% over the past 90 days and is down 7.44% year to date. The 1 year total shareholder return of 72.38% and 3 year total...
NYSE:ORCL
NYSE:ORCLSoftware

Oracle Stock Leads 3 Founder Led AI Infrastructure Picks For Long Term Investors

Global markets are being pulled in different directions by inflation questions, shifting rate expectations and uneven growth across regions. In this kind of backdrop, many investors are looking past quarterly headlines and focusing on founders who are deeply invested in the long term. The Top Founder-Led Companies screener targets leaders with significant skin in the game and tight capital discipline. That combination can help align your interests with theirs, regardless of which sector is in...
NYSE:BLX
NYSE:BLXDiversified Financial

Is Bladex (BLX) Still Undervalued As Earnings And Dividend Support Its Rally?

Bladex (BLX) drew fresh investor attention after reporting second quarter 2026 results that showed higher net interest income and net income than a year earlier, along with an affirmed quarterly dividend for shareholders. See our latest analysis for Bladex. Bladex shares trade at US$58.55 after a 33.61% year to date share price return. The 57.23% 1 year total shareholder return and very large 5 year total shareholder return suggest momentum has been building around the earnings and dividend...
NYSE:DLB
NYSE:DLBSoftware

Does Dolby (DLB) Supercharged Buyback Plan Reframe Its Long‑Term Risk and Capital Allocation Story?

In late July 2026, Dolby Laboratories reported third‑quarter results showing revenue of US$305 million and net income of US$28.6 million, alongside new fourth‑quarter and full‑year 2026 guidance, a US$0.36 dividend, and an expanded share repurchase authorization to US$3.65 billion. Although quarterly profit eased year on year, Dolby’s decision to raise its buyback capacity and maintain dividends underscores management’s emphasis on returning cash to shareholders while its licensing programs...
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Coinbase Stock Leads 3 Founder Led Picks Built For Long Term Investors

Founder led companies can offer something many investors value in markets shaped by inflation questions, interest rate uncertainty and uneven growth data. These leaders often have more of their own wealth tied to the business, which can create strong focus on capital allocation, resilience and long term value. The Founder-Led Companies screener is built to help you find these committed operators without having to sift through every stock yourself. In this article you will see three of the...
NYSE:WH
NYSE:WHHospitality

Does Stronger Margins And Upgraded 2026 Outlook Change The Bull Case For Wyndham Hotels & Resorts (WH)?

In July 2026, Wyndham Hotels & Resorts reported second-quarter revenue of US$375 million, down from US$397 million a year earlier, while net income increased to US$102 million and diluted earnings per share from continuing operations rose to US$1.36 from US$1.13. Alongside higher earnings, the company raised its full-year 2026 net revenue and global RevPAR outlook and continued its multi-year share repurchase program, signaling confidence in its business model and cash generation. Now we’ll...
NasdaqGS:XRX
NasdaqGS:XRXTech

Xerox (XRX) Is Up 14.3% After Raising 2026 Guidance And Lexmark Synergy Targets – What's Changed

In July 2026, Xerox Holdings Corporation reported second-quarter results showing revenue of US$1,922 million and net income of US$13 million, alongside a smaller six-month net loss and higher year-to-date revenue versus the prior year. The company also raised its full-year 2026 guidance to approximately US$7.60 billion in revenue and increased synergy targets from its Lexmark collaboration, highlighting progress on priorities to stabilize revenue, improve profitability, and reduce...
NYSE:BTU
NYSE:BTUOil and Gas

Peabody Energy (BTU) Reports Sales Growth And A Net Loss, Is The Stock Still Undervalued?

Peabody Energy (BTU) has drawn fresh attention after second quarter results on July 29 showed higher sales and a shift to a net loss, along with a dividend affirmation and an update on its ongoing share repurchase program. See our latest analysis for Peabody Energy. The earnings release appears to have cooled short term sentiment around Peabody Energy, with the share price down 6.5% over the past week and 30.5% year to date, although the 1 year total shareholder return of 34.3% and 5 year...
NasdaqGS:CORZ
NasdaqGS:CORZSoftware

Is Core Scientific (CORZ) A Bargain After Its AMD AI Infrastructure Deal?

Core Scientific (CORZ) is back in focus after announcing a long-term AI infrastructure agreement with AMD that targets up to 2.5 gigawatts of data center capacity and a 15-year high performance computing colocation deal. See our latest analysis for Core Scientific. The AMD agreement comes as Core Scientific’s share price has eased in the short term, with a 1-day share price return of 5.0% lower and a 7-day return of 8.92% lower. However, the year-to-date share price return of 29.58% and...
NYSE:BDX
NYSE:BDXMedical Equipment

Is BD (BDX) Quietly Building a GLP-1 Delivery Moat With Its Brazil Semaglutide Partnership?

BD (Becton, Dickinson and Company) and EMS previously announced a collaboration to launch a semaglutide therapy in Brazil, using BD’s Vystra Injection Pen platform designed for ease of use in treating chronic conditions such as obesity and type 2 diabetes. This partnership highlights how BD’s drug delivery expertise is being applied to support rising demand for injectable GLP-1 therapies in a major emerging healthcare market. Next, we’ll examine how BD’s role in semaglutide delivery through...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

The Bull Case For Incyte (INCY) Could Change Following New EU Opzelura Atopic Dermatitis Approval

In late July 2026, the European Commission approved Incyte’s Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis whose disease is inadequately controlled by, or unsuitable for, topical corticosteroids and calcineurin inhibitors, following supportive Phase 3b TRuE-AD4 data showing significant symptom improvement and a favorable 24-week safety profile. This second European indication for Opzelura, alongside its existing approval in non-segmental vitiligo, deepens Incyte’s...
NYSE:OC
NYSE:OCBuilding

Owens Corning (OC) Could Be 5% Undervalued As New Leadership Takes Shape

Owens Corning (OC) is back in focus after announcing a reshaped leadership team, with Jonathan Collins set to become Chief Financial Officer and Executive Vice President, and Todd W. Fister promoted to President and Chief Operating Officer. See our latest analysis for Owens Corning. Owens Corning’s latest leadership changes land at a time when the stock is trading at US$138.90, with a 90 day share price return of 13.18% and a more muted 1 year total shareholder return of 4.30%. This suggests...
NYSE:SSB
NYSE:SSBBanks

SouthState Bank (SSB) Stock Looks Cheap, But Can Margins Hold

SouthState Bank stock barely flinched after earnings. The share price ticked down around 0.2% to about US$105, even as the quarterly report put a different story on the table. Return on tangible common equity of 17.6% and net profit margins of 35.5% over the last twelve months speak to a bank still producing solid profitability while trading on a P/E of roughly 10.7x and at a sizeable gap to one discounted cash flow estimate of fair value. For investors thinking beyond this week’s tiny move,...
NYSE:ABBV
NYSE:ABBVBiotechs

AbbVie (ABBV) Stock Faces A Pivotal Growth Handoff After Guidance Lift

AbbVie stock slipped about 2.5% today and is roughly flat over the past month, even after a strong second quarter that pushed adjusted earnings per share to $3.65 and revenue to nearly $17.0b. The market is reacting to the near term. The numbers are pointing you to a longer story. The headline is simple. AbbVie just delivered double digit revenue growth in a period when investors are still focused on legacy patent risks and a very rich trailing P/E of about 123x. The real question now is how...